Outcome by mutation status and line of treatment in optic, a dose-ranging study of 3 starting doses of ponatinib in patients with CP-CML Meeting Abstract
| Authors: | Cortes, J. E.; Apperley, J.; Hochhaus, A.; Mauro, M. J.; Rousselot, P.; Sacha, T.; Talpaz, M.; Chuah, C.; Lipton, J. H.; Deininger, M. W.; Schiffer, C. A.; Maness, L. J.; McCloskey, J. K.; Gutiérrez, V. G.; de Lavallade, H.; Etienne, G.; Lu, V.; Srivastava, S.; Rosti, G. |
| Abstract Title: | Outcome by mutation status and line of treatment in optic, a dose-ranging study of 3 starting doses of ponatinib in patients with CP-CML |
| Meeting Title: | 62nd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 136 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2020 Dec 5-8 |
| Meeting Location: | Virtual |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2020-11-05 |
| Language: | English |
| ACCESSION: | WOS:000607547200134 |
| DOI: | 10.1182/blood-2020-135883 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 44 -- Source: Wos |
